Market Currents
AVI Biopharma (AVII) announces that it landed FDA approval to proceed with a modified dosing of...
-
Tuesday, February 28, 2012, 8:43 AM ETAVI Biopharma (AVII) announces that it landed FDA approval to proceed with a modified dosing of AVI-6003 for treatment of Marburg virus infections after positive testing of the drug on non-human primates. Shares +12.2% premarket.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
